Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
165 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Spinal Cord Injury - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Spinal Cord Injury - Pipeline Review, H2 2014', provides an overview of the Spinal Cord Injury's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Spinal Cord Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Cord Injury and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Spinal Cord Injury - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Spinal Cord Injury and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Spinal Cord Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Spinal Cord Injury pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Spinal Cord Injury - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Spinal Cord Injury pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Spinal Cord Injury Overview 8 Therapeutics Development 9 Pipeline Products for Spinal Cord Injury - Overview 9 Pipeline Products for Spinal Cord Injury - Comparative Analysis 10 Spinal Cord Injury - Therapeutics under Development by Companies 11 Spinal Cord Injury - Therapeutics under Investigation by Universities/Institutes 14 Spinal Cord Injury - Pipeline Products Glance 16 Clinical Stage Products 16 Early Stage Products 17 Spinal Cord Injury - Products under Development by Companies 18 Spinal Cord Injury - Products under Investigation by Universities/Institutes 20 Spinal Cord Injury - Companies Involved in Therapeutics Development 21 Athersys, Inc. 21 Quark Pharmaceuticals, Inc. 22 Acorda Therapeutics, Inc. 23 BioMarin Pharmaceutical Inc. 24 Lpath, Inc. 25 Remedy Pharmaceuticals, Inc. 26 TissueGene, Inc. 27 BioArctic Neuroscience AB 28 Grupo Ferrer Internacional, S.A. 29 AIM Therapeutics Inc. 30 Omeros Corporation 31 FirstString Research, Inc. 32 Stemedica Cell Technologies, Inc. 33 SanBio, Inc. 34 Sirnaomics, Inc. 35 Lipopharma Therapeutics SL 36 Mapreg S.A.S. 37 Asubio Pharma Co., Ltd. 38 PharmatrophiX, Inc. 39 RhinoCyte, Inc. 40 MandalMed, Inc. 41 Faron Pharmaceuticals Oy 42 K-Stemcell Co., Ltd. 43 Vicore Pharma AB 44 Axerion Therapeutics, Inc. 45 Genervon Biopharmaceuticals, LLC 46 Hemostemix Ltd 47 Spinal Cord Injury - Therapeutics Assessment 48 Assessment by Monotherapy Products 48 Assessment by Target 49 Assessment by Mechanism of Action 52 Assessment by Route of Administration 55 Assessment by Molecule Type 57 Drug Profiles 60 SUN-13837 - Drug Profile 60 Stem Cell Therapy for Central Nervous System Disorders - Drug Profile 61 Stem Cell Therapy - Drug Profile 62 OPC-1 - Drug Profile 64 GM-603 - Drug Profile 66 Astrostem - Drug Profile 67 MAP-4343 - Drug Profile 68 glyburide - Drug Profile 69 MultiStem - Drug Profile 72 Lpathomab - Drug Profile 75 siRNA for CNS Disorders - Drug Profile 76 AIM-101 - Drug Profile 77 Enzyme To Inhibit Chondroitin Sulfate Proteoglycan For Spinal Cord Injury And Brain Injury - Drug Profile 78 cimaglermin alfa - Drug Profile 79 SB-623 - Drug Profile 81 NRP-2945 - Drug Profile 82 SB-618 - Drug Profile 84 interferon beta-1a - Drug Profile 85 LM11A-31 - Drug Profile 87 LPA-181 - Drug Profile 88 C-21 - Drug Profile 89 CM-101 - Drug Profile 91 Recombinant Human Fibroblast Growth Factor 1 - Drug Profile 93 PT-00114 - Drug Profile 95 Stem Cell Therapy For Spinal Cord Injury - Drug Profile 96 RhinoCytes - Drug Profile 97 Small Molecule to Activate Chondroitin Sulfate for Spinal Cord Injury - Drug Profile 99 AP-325 - Drug Profile 100 Neural Stem Cells - Drug Profile 101 NgR(310)ecto-Fc - Drug Profile 103 HBN-1 - Drug Profile 105 Connexin-Based Peptide for Spinal Cord Injuries - Drug Profile 106 miR-29b - Drug Profile 107 FIB-117 - Drug Profile 108 Stem Cell Therapy for CNS - Drug Profile 109 Recombinant Protein for Spinal Cord Injury - Drug Profile 110 Neural Stem Cells - Drug Profile 111 Small Molecules for CNS - Drug Profile 112 AX-007 - Drug Profile 113 Stem Cell Therapy for Spinal Cord Injury - Drug Profile 114 Antibody for Spinal Cord Injury - Drug Profile 115 NCP-01 - Drug Profile 116 Tenascin-C Fragments for Spinal Cord Injury - Drug Profile 117 Cell Therapy for Spinal Cord and Traumatic Brain Injury - Drug Profile 119 IMS-001 - Drug Profile 120 IMS-002 - Drug Profile 121 Drug to Inhibit EphA4 for Spinal Cord Injury - Drug Profile 122 STP-805 - Drug Profile 123 TG-N - Drug Profile 124 Small Molecule to Antagonize GPR17 for Central Nervous System Disorders - Drug Profile 125 ICCN-100 - Drug Profile 126 Small Molecules for Spinal Cord Injury - Drug Profile 127 chondroitinase ABC nanosphere - Drug Profile 128 Rnai Therapy For Spinal Cord Injury - Drug Profile 129 Spinal Cord Injury - Recent Pipeline Updates 130 Spinal Cord Injury - Dormant Projects 149 Spinal Cord Injury - Discontinued Products 150 Spinal Cord Injury - Product Development Milestones 151 Featured News & Press Releases 151 Appendix 160 Methodology 160 Coverage 160 Secondary Research 160 Primary Research 160 Expert Panel Validation 160 Contact Us 161 Disclaimer 161
List of Tables Number of Products under Development for Spinal Cord Injury, H2 2014 13 Number of Products under Development for Spinal Cord Injury - Comparative Analysis, H2 2014 14 Number of Products under Development by Companies, H2 2014 16 Number of Products under Development by Companies, H2 2014 (Contd..1) 17 Number of Products under Investigation by Universities/Institutes, H2 2014 19 Comparative Analysis by Clinical Stage Development, H2 2014 20 Comparative Analysis by Early Stage Development, H2 2014 21 Products under Development by Companies, H2 2014 22 Products under Development by Companies, H2 2014 (Contd..1) 23 Products under Investigation by Universities/Institutes, H2 2014 24 Spinal Cord Injury - Pipeline by Athersys, Inc., H2 2014 25 Spinal Cord Injury - Pipeline by Quark Pharmaceuticals, Inc., H2 2014 26 Spinal Cord Injury - Pipeline by Acorda Therapeutics, Inc., H2 2014 27 Spinal Cord Injury - Pipeline by BioMarin Pharmaceutical Inc., H2 2014 28 Spinal Cord Injury - Pipeline by Lpath, Inc., H2 2014 29 Spinal Cord Injury - Pipeline by Remedy Pharmaceuticals, Inc., H2 2014 30 Spinal Cord Injury - Pipeline by TissueGene, Inc., H2 2014 31 Spinal Cord Injury - Pipeline by BioArctic Neuroscience AB, H2 2014 32 Spinal Cord Injury - Pipeline by Grupo Ferrer Internacional, S.A., H2 2014 33 Spinal Cord Injury - Pipeline by AIM Therapeutics Inc., H2 2014 34 Spinal Cord Injury - Pipeline by Omeros Corporation, H2 2014 35 Spinal Cord Injury - Pipeline by FirstString Research, Inc., H2 2014 36 Spinal Cord Injury - Pipeline by Stemedica Cell Technologies, Inc., H2 2014 37 Spinal Cord Injury - Pipeline by SanBio, Inc., H2 2014 38 Spinal Cord Injury - Pipeline by Sirnaomics, Inc., H2 2014 39 Spinal Cord Injury - Pipeline by Lipopharma Therapeutics SL, H2 2014 40 Spinal Cord Injury - Pipeline by Mapreg S.A.S., H2 2014 41 Spinal Cord Injury - Pipeline by Asubio Pharma Co., Ltd., H2 2014 42 Spinal Cord Injury - Pipeline by PharmatrophiX, Inc., H2 2014 43 Spinal Cord Injury - Pipeline by RhinoCyte, Inc., H2 2014 44 Spinal Cord Injury - Pipeline by MandalMed, Inc., H2 2014 45 Spinal Cord Injury - Pipeline by Faron Pharmaceuticals Oy, H2 2014 46 Spinal Cord Injury - Pipeline by K-Stemcell Co., Ltd., H2 2014 47 Spinal Cord Injury - Pipeline by Vicore Pharma AB, H2 2014 48 Spinal Cord Injury - Pipeline by Axerion Therapeutics, Inc., H2 2014 49 Spinal Cord Injury - Pipeline by Genervon Biopharmaceuticals, LLC, H2 2014 50 Spinal Cord Injury - Pipeline by Hemostemix Ltd, H2 2014 51 Assessment by Monotherapy Products, H2 2014 52 Number of Products by Stage and Target, H2 2014 55 Number of Products by Stage and Mechanism of Action, H2 2014 58 Number of Products by Stage and Route of Administration, H2 2014 60 Number of Products by Stage and Molecule Type, H2 2014 63 Spinal Cord Injury Therapeutics - Recent Pipeline Updates, H2 2014 134 Spinal Cord Injury - Dormant Projects, H2 2014 153 Spinal Cord Injury - Discontinued Products, H2 2014 154
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
